Seven New Insulin Products to be Locally Produced in Saudi Arabia
Saudi Arabia signed an agreement to produce at least seven insulin products locally, enhancing its pharmaceutical capabilities and supporting Vision 2030’s goals for health security.
On Tuesday, Saudi Arabia signed an agreement to localize at least seven insulin products. The ceremony took place during the Global Health Exhibition in Riyadh and was attended by notable figures, including Minister of Health Fahad Al-Jalajel, Minister of Investment Khalid Al-Falih, and Minister of Industry and Mineral Resources Bandar Alkhorayef.
This agreement was forged in collaboration with the National Unified Procurement Company for Medical Supplies (NUPCO), Sudair Pharmaceutical Company, Sanofi, and Novo Nordisk. It underscores Saudi Arabia's commitment to boosting local production capabilities while fostering an attractive investment climate, in alignment with the goals set out in Saudi Vision 2030.
The initiative aims to bolster efforts by government agencies, including the Ministries of Health, Investment, and Industry and Mineral Resources, to localize the medical and pharmaceutical sectors. This move aims to achieve drug and health security in the Kingdom while ensuring that domestic pharmaceutical needs and requirements are met effectively.
Related Articles
Trending This Week
SceneNow TV
Events Calendar
